Search
Search Results
-
Long-acting injectable paliperidone palmitate induced severe cutaneous allergic reaction in a patient with first episode delusional disorder tolerating oral paliperidone regimen: a case report
BackgroundPaliperidone is a second-generation antipsychotic agent that is effective in the treatment of schizophrenia and schizoaffective disorder as...
-
Paliperidone palmitate vs. paliperidone extended-release for the acute treatment of adults with schizophrenia: a systematic review and pairwise and network meta-analysis
Is paliperidone palmitate (PP) a useful treatment option for adults with acute symptoms of schizophrenia? We conducted a systematic review and a...
-
Model-Informed Clinical Development of 6-Monthly Injection of Paliperidone Palmitate in Patients with Schizophrenia: Dosing Strategies Guided by Population Pharmacokinetic Modeling and Simulation (Part II)
Background and ObjectivePaliperidone palmitate 6-month (PP6M) intramuscular (IM) injection is the longest-acting treatment available for patients...
-
Adis summary of research: A 10-year observational study of the use, acceptability and effectiveness of long-acting paliperidone palmitate: implications for clinical decision making
Atypical long-acting injectable antipsychotics, such as paliperidone palmitate, play an important role in the management of psychotic disorders. They...
-
Crystal structures and properties of two aromatic carboxylic acid-based medicinal salts of paliperidone
Two pharmaceutical salts of paliperidone, namely, paliperidone benzoate (PLPT·BA) and paliperidone salicylate (PLPT·SA), were successfully...
-
Safety and Efficacy of Paliperidone Palmitate in Pediatric Patients with Autism and Intellectual Disability
This retrospective chart review examines the safety, tolerability and effectiveness of long acting injectable paliperidone palmitate (P-LAI)...
-
Health economics study of paliperidone palmitate in the treatment of schizophrenia: a 12-month cohort study
BackgroundTo analyze the economic benefits of paliperidone palmitate in the treatment of schizophrenia.
MethodsWe collected 546 patients who met the...
-
Model-Informed Clinical Development of Once-Every-6-Month Injection of Paliperidone Palmitate in Patients with Schizophrenia: A Pharmacometric Bridging Approach (Part I)
Background and ObjectiveA model-informed drug development (MIDD) approach was implemented for paliperidone palmitate (PP) 6-month (PP6M) clinical...
-
Paliperidone palmitate intramuscular 6-monthly formulation in schizophrenia: a profile of its use
The 6-monthly formulation of intramuscular paliperidone palmitate [INVEGA HAFYERA ™ (USA); BYANNLI ® (EU)] represents a useful and convenient...